1. Inicio
  2. Publicaciones
  3. Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial

Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial

Fecha de publicación: Fecha Ahead of Print:

Autores organización

Autores

  • Arrieta O
  • Zatarain-Barrón ZL
  • Turcott JG
  • Barrón F
  • Yendamuri S
  • Rosell R

Grupos de investigación

Resumen

[No abstract available]

Datos de la publicación

ISSN/ISSNe:
2374-2437, 2374-2445

Jama Oncology  American Medical Association

Tipo:
Letter
Páginas:
477-479
Enlace a otro recurso:
www.scopus.com

Citas Recibidas en Web of Science: 11

Citas Recibidas en Scopus: 19

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Adenocarcinoma of Lung; Body Mass Index; ErbB Receptors; Humans; Lung Neoplasms; Metformin; Mutation; Protein Kinase Inhibitors; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; metformin; epidermal growth factor receptor; metformin; protein kinase inhibitor; adult; body mass; cancer patient; cancer survival; controlled study; EGFR gene; female; human; independent variable; informed consent; Letter; lung adenocarcinoma; major clinical study; male; Mexico; non small cell lung cancer; overall survival; phase 2 clinical trial; progression free survival; randomized controlled trial; body mass; clinical trial; genetics; lung tumor; mutation

Campos de estudio

Proyectos asociados

EFECTO DEL EXTRACTO DE Trametes versicolor SOBRE EL FENOTIPO Y LA FUNCIÓN DE CÉLULAS DENDRÍTICAS HUMANAS CONDICIONADAS CON MEDIOS DE CÉLULAS DE CARCINOMA ORAL

Investigador Principal: ANDRES FELIPE CARDONA MENDOZA

PCI-2019-10805 . 2020

Citar la publicación

Compartir la publicación